trastuzumab-qyyp Trazimera
Selected indexed studies
- Trastuzumab Deruxtecan: First Approval. (Drugs, 2020) [PMID:32144719]
- Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. (Cancer Commun (Lond), 2023) [PMID:37434399]
- Trastuzumab-Induced Cardiomyopathy. (Cardiol Clin, 2019) [PMID:31587782]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trastuzumab Deruxtecan: First Approval. (2020) pubmed
- Trastuzumab-Induced Cardiomyopathy. (2019) pubmed
- Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. (2023) pubmed
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008) pubmed
- Trastuzumab-associated cardiotoxicity. (2002) pubmed
- Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. (2022) pubmed
- Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera(TM)), a trastuzumab biosimilar, under extended in-use conditions. (2023) pubmed
- Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. (2022) pubmed
- PF-05280014: A Trastuzumab Biosimilar. (2018) pubmed
- ABP 980: A Trastuzumab Biosimilar. (2018) pubmed